Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4

被引:6
|
作者
Borzsei, Rita [1 ,2 ,3 ]
Zsido, Balazs Zoltan [1 ,2 ,3 ]
Balint, Monika [1 ,2 ,3 ]
Helyes, Zsuzsanna [1 ,2 ,3 ,4 ,5 ]
Pinter, Erika [1 ,2 ,3 ,4 ,5 ]
Hetenyi, Csaba [1 ,2 ,3 ]
机构
[1] Univ Pecs, Med Sch, Dept Pharmacol & Pharmacotherapy, H-7624 Pecs, Hungary
[2] Univ Pecs, Janos Szentagothai Res Ctr, H-7624 Pecs, Hungary
[3] Univ Pecs, Ctr Neurosci, H-7624 Pecs, Hungary
[4] Algonist Gmbh, A-1030 Vienna, Austria
[5] PharmInVivo Ltd, H-7624 Pecs, Hungary
关键词
pocket; site; peptide; interaction; selectivity; dynamics; CYCLIC HEXAPEPTIDE ANALOG; TRANSMEMBRANE DOMAIN; CONFORMATIONAL PROPERTIES; AGONIST J-2156; IDENTIFICATION; SELECTIVITY; RELEASE; POTENTIALS; ACTIVATION; LIGANDS;
D O I
10.3390/ijms23136878
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Somatostatin (also named as growth hormone-inhibiting hormone or somatotropin release-inhibiting factor) is a regulatory peptide important for the proper functioning of the endocrine system, local inflammatory reactions, mood and motor coordination, and behavioral responses to stress. Somatostatin exerts its effects via binding to G-protein-coupled somatostatin receptors of which the fourth subtype (SSTR4) is a particularly important receptor mediating analgesic, anti-inflammatory, and anti-depressant effects without endocrine actions. Thus, SSTR4 agonists are promising drug candidates. Although the knowledge of the atomic resolution-binding modes of SST would be essential for drug development, experimental elucidation of the structures of SSTR4 and its complexes is still awaiting. In the present study, structures of the somatostatin-SSTR4 complex were produced using an unbiased, blind docking approach. Beyond the static structures, the binding mechanism of SST was also elucidated in the explicit water molecular dynamics (MD) calculations, and key binding modes (external, intermediate, and internal) were distinguished. The most important residues on both receptor and SST sides were identified. An energetic comparison of SST binding to SSTR4 and 2 offered a residue-level explanation of receptor subtype selectivity. The calculated structures show good agreement with available experimental results and indicate that somatostatin binding is realized via prerequisite binding modes and an induced fit mechanism. The identified binding modes and the corresponding key residues provide useful information for future drug design targeting SSTR4.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Somatostatin receptor subtype 4 mediates the antiepileptic actions of somatostatin in hippocampus
    Qiu, C
    Suzuki, C
    de Lecca, L
    Tallent, MK
    EPILEPSIA, 2004, 45 : 23 - 23
  • [2] A computational study of somatostatin subtype-4 receptor agonist binding
    Olivia Slater
    Maria Kontoyianni
    SN Applied Sciences, 2022, 4
  • [3] A computational study of somatostatin subtype-4 receptor agonist binding
    Slater, Olivia
    Kontoyianni, Maria
    SN APPLIED SCIENCES, 2022, 4 (05):
  • [4] Superagonism at the human somatostatin receptor subtype 4
    Engström, M
    Tomperi, J
    El-Darwish, K
    Åhman, M
    Savola, JM
    Wurster, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (01): : 332 - 338
  • [5] Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2
    Sharif, Nadder
    Gendron, Louis
    Wowchuk, Julia
    Sarret, Philippe
    Mazella, Jean
    Beaudet, Alain
    Stroh, Thomas
    ENDOCRINOLOGY, 2007, 148 (05) : 2095 - 2105
  • [6] Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2
    John, M
    Meyerhof, W
    Richter, D
    Waser, B
    Schaer, JC
    Scherubl, H
    BoeseLandgraf, J
    Neuhaus, P
    Ziske, C
    Molling, K
    Riecken, EO
    Reubi, JC
    Wiedenmann, B
    GUT, 1996, 38 (01) : 33 - 39
  • [7] Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma
    Mato, E
    Matías-Guiu, X
    Chico, A
    Webb, SM
    Cabezas, R
    Berná, L
    De Leiva, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07): : 2417 - 2420
  • [8] Nonpeptide somatostatin agonists with selectivity for the subtype 4 receptor.
    Crider, AM
    Liu, SQ
    Tang, C
    Ho, B
    Ankersen, M
    Stidsen, CE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U1019 - U1019
  • [9] Somatostatin subtype receptor 4 expression in mouse and rat retina
    Brecha, N
    Vila, A
    Allen, J
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U647 - U647
  • [10] Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies
    Janson, ET
    Stridsberg, M
    Gobl, A
    Westlin, JE
    Öberg, K
    CANCER RESEARCH, 1998, 58 (11) : 2375 - 2378